Age in years, mean (SD) | 54.8 (14) |
---|---|
Symptom duration in months (n = 166) | 4.6 |
Gender, % female | 64% |
DAS28, mean (SD) | 4.9 (1.3) |
SJC28 at baseline | 6 (3–11) |
TJC28 at baseline | 6 (2–10) |
ESR (n = 173) | 27 (12–47) |
VAS, mean (SD) | 51 (24) |
RF, % positive (n = 171) | 67% |
aCCP, % positive (n = 171) | 60% |
RF and aCCP, % positive (n = 171) | 54% |
HAQ (n = 155), | 0.88 (0.38–1.25) |
USJC | 5 (2–9) |